0001564590-21-045775.txt : 20210826 0001564590-21-045775.hdr.sgml : 20210826 20210825182211 ACCESSION NUMBER: 0001564590-21-045775 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20210825 FILED AS OF DATE: 20210826 DATE AS OF CHANGE: 20210825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 211208162 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190847081 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 bntx-6k_20210825.htm 6-K bntx-6k_20210825.DOCX.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF AUGUST 2021

COMMISSION FILE NUMBER 001-39081

BioNTech SE
(Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐


DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On August 25, 2021, BioNTech SE (the “Company”) and Pfizer Inc. today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster (third) dose of COMIRNATY® (COVID-19 vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The companies intend to complete submission of the sBLA by the end of this week. The press release is attached hereto as Exhibit 99.1.

 

 


SIGNATURE

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

BioNTech SE

 

 

 

 

 

 

 

By:

/s/ Dr. Sierk Poetting

 

 

Name: Dr. Sierk Poetting

 

 

Title:   Chief Operating Officer

Date: August 25, 2021


EXHIBIT INDEX

 

 

 

 EX-99.1 2 bntx-ex991_6.htm EX-99.1 bntx-ex991_6.htm

Exhibit 99.1

 

 

 

Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older

 

 

•

New Phase 3 data show booster (third) dose of COMIRNATY induces significant SARS-CoV-2 neutralizing antibody titers and demonstrated a favorable safety and tolerability profile

 

•

SARS-CoV-2 neutralizing titers against the wild-type strain one month after booster dose were 3.3 times the titers one month after the second dose

 

•

Pfizer and BioNTech intend to file these data with the European Medicines Agency (EMA) and other regulatory authorities around the world in coming weeks

 

NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of a booster (third) dose of COMIRNATY® (COVID-19 vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The companies intend to complete submission of the sBLA by the end of this week.

 

The sBLA includes data from a Phase 3 clinical trial of 306 participants 18-55 years of age who received a booster (third) dose of COMIRNATY, between 4.8 and 8 months after completing the two-dose primary regimen, with a median follow-up time of 2.6 months post booster. The booster (third) dose of COMIRNATY elicited robust neutralizing antibodies to the wild-type strain in participants who were without evidence of SARS-CoV-2 infection through one month post dose three. SARS-CoV-2 50% neutralizing titers (PRNT50) after the third dose were 3.3 times the titers after the second dose. The post dose three neutralizing titers met the prespecified 1.5-fold non-inferiority criterion for success and were statistically superior. Moreover, 99.5% of participants had a four-fold response after the third dose, compared to 98.0% after the second dose. The titers after dose three met the pre-specified 10% non-inferiority margin for the difference in the four-fold seroresponse rates.

 

The reactogenicity profile within seven days after the booster (third) dose was typically mild to moderate. The most common events included injection site pain, fatigue, headache, muscle and joint pain, and chills. The frequency of any severe systemic event after the booster dose was low. The frequency of reactogenicity was similar to or better than after dose two of the primary series. The adverse event profile was generally consistent with other clinical data for COMIRNATY.

 

Pfizer and BioNTech intend to submit these data to a peer reviewed journal, as well as file these data with the European Medicines Agency (EMA) and other regulatory authorities around the world in the coming weeks.

 

A third dose of the Pfizer-BioNTech vaccine is not currently authorized for broad use in the U.S. However, under the current amended Emergency Use Authorization, a third dose was authorized on August 12 for administration to individuals at least 12 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

 

COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union and the United Kingdom, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer), Canada and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

 

Indication & Authorized Use

COMIRNATY® (COVID-19 vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.

1

 

 

•

It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older

 

•

It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:

 

o

prevent COVID-19 in individuals 12 through 15 years, and

 

o

provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

 

The Pfizer-BioNTech COVID-19 vaccine has received EUA from FDA to:

 

•

prevent COVID-19 in individuals 12 years of age and older, and

 

•

provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

 

The FDA-approved COMIRNATY® (COVID-19 vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.

 

EUA Statement

This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

 

Important Safety Information  

Individuals should not get the Pfizer-BioNTech COVID-19 vaccine if they: 

 

•

had a severe allergic reaction after a previous dose of this vaccine 

 

•

had a severe allergic reaction to any ingredient of this vaccine  

 

Individuals should tell the vaccination provider about all of their medical conditions, including if they: 

 

•

have any allergies 

 

•

have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart) 

 

•

have a fever 

 

•

have a bleeding disorder or are on a blood thinner 

 

•

are immunocompromised or are on a medicine that affects the immune system 

 

•

are pregnant, plan to become pregnant, or are breastfeeding 

 

•

have received another COVID-19 vaccine 

 

•

have ever fainted in association with an injection 

 

The vaccine may not protect everyone. 

 

Side effects reported with the vaccine include: 

 

•

There is a remote chance that the vaccine could cause a severe allergic reaction 

 

o

A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination 

 

o

Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness 

 

o

If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital 

 

•

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:  

2

 

 

o

chest pain 

 

o

shortness of breath 

 

o

feelings of having a fast-beating, fluttering, or pounding heart 

 

•

Side effects that have been reported with the vaccine include: 

 

o

severe allergic reactions; non-severe allergic reactions such as rash, itching, hives, or swelling of the face; myocarditis (inflammation of the heart muscle); pericarditis (inflammation of the lining outside the heart); injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain 

 

•

These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away 

 

There is no information on the use of the vaccine with other vaccines. 

 

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1‐800‐822‐7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985. 

Please click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).

 

 

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

 

Pfizer Disclosure Notice

The information contained in this release is as of August 25, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

 

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and the rolling submission of a sBLA for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study;  the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3

3

 

trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when the submission of the sBLA for a potential booster (third) dose in the U.S. will be completed and accepted for review, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

 

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

 

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not

4

 

be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including the definite approval of the BLA for BNT162b2 to prevent COVID-19 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of BNT162b2 in individuals 16 years of age and older and/or a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence, a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

 

For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

 

Pfizer Contacts:

Media Relations

Amy Rose

+1 (212) 733-7410

Amy.Rose@pfizer.com

 

Investor Relations

Chuck Triano

+1 (212) 733-3901

Charles.E.Triano@Pfizer.com

 

BioNTech Contacts:

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

Media@biontech.de

 

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

Investors@biontech.de

 

 

5

 

 GRAPHIC 3 gi000okroa0j000001.jpg GRAPHIC begin 644 gi000okroa0j000001.jpg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end GRAPHIC 4 gi000okroa0j000002.jpg GRAPHIC begin 644 gi000okroa0j000002.jpg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end